United States Chronic Inflammatory Demyelinating Polyneuropathy Market 2024-2031: In-Depth Analysis of Immunoglobulin Therapy, Corticosteroids, Plasma Exchange, and Emerging Biologics | Top Companies are Grifols, Baxter, Kedrion S.p.A

Chronic Inflammatory Demyelinating Polyneuropathy Market is valued at a significant CAGR during the forecast period (2024-2031).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that leads to progressive weakness, numbness, and sensory impairment in the limbs. Current treatments include corticosteroids, intravenous immunoglobulin (IVIg), plasma exchange (plasmapheresis), and emerging biologics. The market is expanding due to increasing disease awareness, advances in therapeutic options, early diagnosis, and growing adoption of patient-centric treatment approaches.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Chronic Inflammatory Demyelinating Polyneuropathy Market Landscape:- https://datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?rk

☛ Chronic Inflammatory Demyelinating Polyneuropathy Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Grifols expanded its immunoglobulin therapy portfolio for CIDP patients in the U.S., offering improved formulations for long-term management.

✅ In July 2025, Octapharma launched next-generation IVIG and subcutaneous immunoglobulin therapies, supporting personalized CIDP treatment plans.

✅ In June 2025, Takeda Pharmaceuticals partnered with U.S. neurology centers to deploy innovative plasma-derived therapies, enhancing symptom management and patient quality of life.

Europe: Recent Industry Developments

✅ In July 2025, Baxalta (Shire, part of Takeda) launched advanced CIDP therapies in EU markets, including subcutaneous immunoglobulin formulations for home administration.

✅ In June 2025, Octapharma Europe expanded its CIDP-focused immunotherapy programs, targeting improved efficacy and reduced adverse effects.

✅ In May 2025, Grifols Europe partnered with hospitals to implement optimized CIDP treatment protocols, supporting patient adherence and long-term outcomes.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Japan launched immunoglobulin therapies for CIDP patients, emphasizing patient convenience and safety.

✅ In June 2025, Kamada Japan expanded its plasma-derived therapy offerings, supporting management of autoimmune neuropathies including CIDP.

✅ In May 2025, Nippon Shinyaku partnered with Japanese neurology centers to implement next-generation CIDP treatment protocols, improving efficacy and quality of care.

☛ Chronic Inflammatory Demyelinating Polyneuropathy Market Trends:

Innovative Therapeutics: Development of subcutaneous immunoglobulin (SCIg), monoclonal antibodies, and targeted immunomodulatory therapies is improving treatment efficacy, reducing side effects, and enhancing patient convenience.

Rising Awareness & Diagnosis: Increased efforts by neurology societies, patient advocacy programs, and healthcare providers are driving early detection and timely intervention.

Market Segmentation: IVIg remains the dominant therapy due to proven efficacy, while emerging biologics and novel formulations are gaining adoption for refractory cases.

Regional Insights: North America and Europe lead due to robust healthcare infrastructure, reimbursement support, and high diagnosis rates. Asia-Pacific is witnessing rapid growth with expanding neurologist awareness, improving healthcare access, and rising patient diagnosis.

Challenges: High therapy costs, long-term treatment requirements, and limited accessibility in developing regions may restrain market growth.

Strategic Initiatives: Companies are focusing on R&D of more effective therapies, collaborations with hospitals and research centers, and patient support programs to improve outcomes and adherence.

☛ Chronic Inflammatory Demyelinating Polyneuropathy Market Competitve Landscape:

Bio Products Laboratory Ltd, Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation,CSL Behring, Teijin Pharma Limited, Pfizer, Inc.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market

☛ Segment Covered in the Chronic Inflammatory Demyelinating Polyneuropathy Market:

By Treatment Type: Immunoglobulin Therapy, Corticosteroids , Immunosuppressants, Physical Therapy, Plasma Exchange.

By Route of Administration: Oral, Intravenous.

By End User: Hospitals, Speciality Clinics, Research and Academic Institutes.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Chronic Inflammatory Demyelinating Polyneuropathy Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market

☛ Regional Analysis for Chronic Inflammatory Demyelinating Polyneuropathy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Chronic Inflammatory Demyelinating Polyneuropathy Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Chronic Inflammatory Demyelinating Polyneuropathy Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Chronic Inflammatory Demyelinating Polyneuropathy Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.